Drugs and FDA

UniQure gene therapy misses significance on four-year Huntington’s disease measure

At 48 months, AMT-130 was linked to 44% slower progression on cUHDRS, but the result was not statistically significant. TFC showed 61% slower progression.

Reported by 2 outlets Wednesday, September 30, 2026

Brain scan images on monitors in an MRI control room
Photo: Public domain, U.S. Navy Medicine

UniQure reported 48-month results for AMT-130, its gene therapy for Huntington’s disease, from 12 people who received the high dose. Compared with an updated external patient database, disease progression on the cUHDRS measure was 44% slower, a result that did not reach statistical significance, the company said. The scale assesses cognition, motor skills and daily living.

On total functional capacity (TFC), a measure focused on daily activities, progression was 61% slower than in the external control, according to UniQure. The company said 53% of the reference data at 48 months was missing. In a post hoc analysis, UniQure reported slowing of 54% on cUHDRS and 68% on TFC.

UniQure has filed for accelerated FDA approval based on earlier 36-month data. The company’s chief medical officer said it was unclear whether the FDA would rerun the analysis using the new data.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.